A study to evaluate the safety, tolerability, and immunogenicity of the Leish-111f + MPL-SE vaccine compared to the Leish-111f protein alone in Montenegro skin test-negative healthy adults

Trial Profile

A study to evaluate the safety, tolerability, and immunogenicity of the Leish-111f + MPL-SE vaccine compared to the Leish-111f protein alone in Montenegro skin test-negative healthy adults

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Aug 2007

At a glance

  • Drugs LEISH-F3 peptide vaccine (Primary) ; Monophosphoryl lipid A (Primary)
  • Indications Leishmaniasis
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 24 Aug 2007 Status change
    • 06 Dec 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top